A
Accriva Diagnostics
Near patient testing systems and advanced diagnostic solutions
About Accriva Diagnostics
Accriva Diagnostics is a pioneering company in the field of in vitro diagnostics, specializing in Hemostasis and Acute Care Diagnostics. Since its inception in 1959, the company has been at the forefront of innovation, consistently delivering high-quality diagnostic systems, reagents, data management solutions, and comprehensive services. Accriva serves a diverse range of clients, including hospitals, laboratories, and intensive care units, ensuring optimal patient care through its advanced diagnostic solutions.
Operating in a global market, Accriva has a significant presence across America, Asia Pacific, Europe, the Middle East, and Africa. The company's business model revolves around the development, manufacturing, and distribution of diagnostic systems and reagents, which are essential for accurate and timely medical diagnostics. Revenue is generated through the sale of these products and the provision of related services, including system optimization, training, and customer support.
Accriva's commitment to quality and innovation is evident in its award-winning products and continuous upward sales trajectory. The company's integrative solutions are designed to support the continuum of hospital care, ensuring that healthcare providers have the tools they need to deliver the highest level of patient care.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2010
- Headquarters
- San Diego, United States
- Employees
- 87
- Open positions
- None listed
- Dealroom signal
- 34.8/100
- Industry
- Health
- Sub-industry
- Medical Devices, Health Platform
- Sector
- Health Tech & Medtech, Testing, Critical medical care, Patient Care, Health Diagnostics, Hard Tech, medical testing, DT and LS, science-based
- Technology
- Deep Tech
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2017 | $0 | — | Werfen | ↗ |
| LATE VC✓Equity / VC | Mar 2015 | $16M | $62M | Warburg Pincus | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Accriva Diagnostics is 150 monthly website visits, down 11.8% over the last three months. Accriva Diagnostics's team declined 24.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- BCBay City Capital
Series B and later1 investor entered at this stage
Other known investors4 additional known investors
Accumetrics
ITC
Werfen
Tony M. Chou
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Accriva Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Accriva Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.